The Gut Hormone-Brain Axis: Mechanisms, Pharmacology, and Treatment in Patients with Adiposity-Based Chronic Disease

Thursday, May 12, 2022

9:15 AM – 10:15 AM

Location: Main Stage - Sapphire IJMN (Level 4)

Speaker(s)

W. Timothy Garvey, MD
Professor
University of Alabama at Birmingham
Mountain Brook, Alabama, United States

Disclosure: Eli Lilly (Self) : site PI of clinical trial sponsored by University of Alabama at Birmingham and funded by Eli Lilly (Status: Ongoing), University Grants/Research Support (Status: Ongoing); Epitomee (Self) : site co-PI of a device trial sponsored by University of Alabama at Birmingham and funded by Epitomee (Status: Ongoing), University Grants/Research Support (Status: Ongoing); Novo Nordisk (Self) : site PI of clinical trial sponsored by University of Alabama at Birmingham and funded by Novo Nordisk (Status: Ongoing), University Grants/Research Support (Status: Ongoing); Pfizer (Self) : site PI of clinical trial sponsored by University of Alabama at Birmingham and funded by Pfizer (Status: Ongoing), University Grants/Research Support (Status: Ongoing)

PDF Slides

Moderator(s)

Monica Agarwal, MD, MEHP, FACE
Associate Professor
University of Alabama at Birmingham
Mountain Brook, Alabama, United States

Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Learning Objectives:

Describe mechanisms by which satiety hormones regulate caloric intake and how these systems become disordered in obesity
Gain an appreciation of the pharmacological approaches to obesity based on satiety hormone physiology that are currently available for treating Adiposity-Based Chronic Disease (ABCD) and those in development
Review the efficacy and safety of new medications that act as satiety hormone agonists, and examine the implications regarding new paradigms of ABCD management

Participants should be aware of the following financial/non-financial relationships:

W. Timothy Garvey, MD: Eli Lilly (Individual(s) Involved: Self): site PI of clinical trial sponsored by University of Alabama at Birmingham and funded by Eli Lilly, University Grants/Research Support; Epitomee (Individual(s) Involved: Self): site co-PI of a device trial sponsored by University of Alabama at Birmingham and funded by Epitomee, University Grants/Research Support; Novo Nordisk (Individual(s) Involved: Self): site PI of clinical trial sponsored by University of Alabama at Birmingham and funded by Novo Nordisk, University Grants/Research Support; Pfizer (Individual(s) Involved: Self): site PI of clinical trial sponsored by University of Alabama at Birmingham and funded by Pfizer, University Grants/Research Support

Monica Agarwal, MD, MEHP, FACE: I do not have any relevant financial / non-financial relationships with any proprietary interests.